ViroGates A/S

ViroGates A/S ROE

The Return on Equity (ROE) of ViroGates A/S (VIRO.CO) as of Nov 5, 2026 is -53.58 %. In the previous year, Return on Equity (ROE) was -132.89 % — a change of -59.68% (higher).

ROE

-53.58 %

YoY

-59.68%

Last updated:

In 2025, ViroGates A/S's return on equity (ROE) was -53.58 %, a -59.68% increase from the -132.89 % ROE in the previous year.

The ViroGates A/S ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-27.84 DKK
Jan 1, 2019
-44.53 DKK
Jan 1, 2020
-59.83 DKK
Jan 1, 2021
-107.53 DKK
Jan 1, 2022
-59.96 DKK
Jan 1, 2023
-71.12 DKK
Jan 1, 2024
-132.89 DKK
Jan 1, 2025
-53.58 DKK
The ViroGates A/S ROE history
YEARROEYoY
-53.58 %-59.68%
-132.89 %+86.84%
-71.12 %+18.62%
-59.96 %-44.24%
-107.53 %+79.72%
-59.83 %+34.37%
-44.53 %+59.93%
-27.84 %-86.06%
-199.77 %+232.20%
-60.13 %+112.58%
-28.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

ViroGates A/S Stock analysis

What does ViroGates A/S do? ViroGates A/S develops and markets prognostic products for the healthcare sector, focusing on the suPARnostic product line that measures soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The suPARnostic Quantitative Point of Care Quick Triage test is designed for patient triage in acute care settings, while the Quantitative ELISA Assay targets clinical routine use. Healthcare providers, including hospitals and clinics, purchase these products to assess immune activation levels and monitor disease progression, particularly for conditions like HIV-1-infection, malaria, tuberculosis, and sepsis. The company generates revenue through the sale of these diagnostic tools to healthcare institutions for use in patient care and disease management. The suPARnostic product line serves as a marker for survival chances upon hospital admission and aids in early intervention by detecting elevated suPAR levels linked to increased inflammation and mortality risk. High suPAR levels are associated with infectious diseases such as Streptococcus pneumonia bacteraemia, pneumococcal pneumonia, and bacterial and viral CNS infections. Healthcare facilities utilize the quantitative tests to determine patient prognosis and guide treatment decisions, ensuring timely interventions that improve patient outcomes. ViroGates A/S monetizes its diagnostic solutions by supplying healthcare systems with tools that enhance clinical decision-making and patient monitoring capabilities. ViroGates A/S targets healthcare providers who require rapid and accurate diagnostic tools for acute care and routine clinical use. The company's products are specifically tailored for monitoring immune activation in patients with infectious diseases, offering both point-of-care testing and laboratory-based assays. By providing these specialized diagnostic solutions, ViroGates A/S supports healthcare institutions in managing patient care more effectively, leading to better health outcomes and reduced mortality rates. Revenue is derived from the direct sale of suPARnostic tests to hospitals, clinics, and other clinical facilities that integrate these tools into their diagnostic workflows. ViroGates A/S is one of the most popular companies on Eulerpool.

ROE Details

Decoding ViroGates A/S's Return on Equity (ROE)

ViroGates A/S's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing ViroGates A/S's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

ViroGates A/S's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in ViroGates A/S’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about ViroGates A/S stock

Return on Equity (ROE) of ViroGates A/S is -53.58 % in 2025.

Return on Equity (ROE) of ViroGates A/S changed from -132.89 % to -53.58 %, representing a -59.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s ViroGates A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — ViroGates A/S

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — ViroGates A/S